| Added by | mollevi |
|---|---|
| Last modified by | llasorsa |
| Group name | EquipeMY |
| Item Type | Journal Article |
| Title | Long-Term Prevalence of Sensory Chemotherapy-Induced Peripheral Neuropathy for 5 Years after Adjuvant FOLFOX Chemotherapy to Treat Colorectal Cancer: A Multicenter Cross-Sectional Study |
| Creator | Selvy et al. |
| Author | Marie Selvy |
| Author | Bruno Pereira |
| Author | Nicolas Kerckhove |
| Author | Coralie Gonneau |
| Author | Gabrielle Feydel |
| Author | Caroline Pétorin |
| Author | Agnès Vimal-Baguet |
| Author | Sergey Melnikov |
| Author | Sharif Kullab |
| Author | Mohamed Hebbar |
| Author | Olivier Bouché |
| Author | Florian Slimano |
| Author | Vincent Bourgeois |
| Author | Valérie Lebrun-Ly |
| Author | Frédéric Thuillier |
| Author | Thibault Mazard |
| Author | David Tavan |
| Author | Kheir Eddine Benmammar |
| Author | Brigitte Monange |
| Author | Mohamed Ramdani |
| Author | Denis Péré-Vergé |
| Author | Floriane Huet-Penz |
| Author | Ahmed Bedjaoui |
| Author | Florent Genty |
| Author | Cécile Leyronnas |
| Author | Jérôme Busserolles |
| Author | Sophie Trevis |
| Author | Vincent Pinon |
| Author | Denis Pezet |
| Author | David Balayssac |
| Abstract | (1) Background: Oxaliplatin is among the most neurotoxic anticancer drugs. Little data are available on the long-term prevalence and consequences of chemotherapy-induced peripheral neuropathy (CIPN), even though the third largest population of cancer survivors is made up of survivors of colorectal cancer. (2) Methods: A multicenter, cross-sectional study was conducted in 16 French centers to assess the prevalence of CIPN, as well as its consequences (neuropathic pain, anxiety, depression, and quality of life) in cancer survivors during the 5 years after the end of adjuvant oxaliplatin chemotherapy. (3) Results: Out of 406 patients, the prevalence of CIPN was 31.3% (95% confidence interval: 26.8-36.0). Little improvement in CIPN was found over the 5 years, and 36.5% of patients with CIPN also had neuropathic pain. CIPN was associated with anxiety, depression, and deterioration of quality of life. None of the patients with CIPN were treated with duloxetine (recommendation from American Society of Clinical Oncology), and only 3.2%, 1.6%, and 1.6% were treated with pregabalin, gabapentin, and amitriptyline, respectively. (4) Conclusions: Five years after the end of chemotherapy, a quarter of patients suffered from CIPN. The present study showed marked psychological distress and uncovered a failure in management in these patients. |
| Publication | Journal of Clinical Medicine |
| Volume | 9 |
| Issue | 8 |
| Date | Jul 27, 2020 |
| Journal Abbr | J Clin Med |
| Language | eng |
| DOI | 10.3390/jcm9082400 |
| ISSN | 2077-0383 |
| Short Title | Long-Term Prevalence of Sensory Chemotherapy-Induced Peripheral Neuropathy for 5 Years after Adjuvant FOLFOX Chemotherapy to Treat Colorectal Cancer |
| Library Catalog | PubMed |
| Extra | PMID: 32727095 |
| Tags | cancer survivors, colorectal cancer, health-related quality of life, oxaliplatin, peripheral neuropathy |
| Date Added | 2020/08/20 - 11:00:07 |
| Date Modified | 2024/10/10 - 16:56:55 |
| Notes and Attachments | PubMed entry (Attachment) Texte intégral (Attachment) Texte intégral (Attachment) |
Institut de Recherche en Cancérologie de
